Introduction {#s1}
============

Many new treatment options make unprecedented outcomes achievable in rheumatoid arthritis (RA).[@R1] [@R2] In parallel, insights on the importance of early effective therapy[@R3] [@R4] and implications of disease activity on function[@R5] [@R6] and joint damage[@R6]--[@R8] led to paradigmatic changes in therapeutic approaches, such as frequent evaluations of disease activity to allow for timely changes of therapies.[@R9]--[@R13] Additionally, validated composite disease activity measures have made disease activity assessment easy.[@R14] [@R15] Nevertheless, heterogeneity of therapeutic aims and patient expectations[@R16] characterise daily practice of RA treatment.[@R17] All this suggests a need to provide rheumatologists and patients with pertinent information on therapeutic targets and means to achieve them.[@R18] [@R19]

Strict definitions of treatment targets intend to facilitate strategic acting in routine care and require physicians and patients to discuss and adopt therapeutic changes within distinct time frames, ideally following therapeutic algorithms. This approach has been utilised in many diseases, like diabetes,[@R20] [@R21] hypertension[@R22]--[@R24] or hyperlipidaemia.[@R25] However, this policy needs to be evidence based to the best possible extent.

Here we report on a systematic review of available evidence regarding the effects of treating RA strategically according to defined outcome targets.

Methods {#s2}
=======

Shaping the systematic literature review {#s3}
----------------------------------------

As a first step, the international steering committee of the Treat-To-Target (T2T) project, comprising a group of expert rheumatologists and a patient (MdW), designed a literature search that aimed at 'treating to target'-strategy trials in RA. The search was then performed by a project fellow (MS), a control search by a second fellow (RK) and by two mentors (DA, DvdH).

The following definitions were made: (1) *strategy trial* -- clinical trial of any RA drug treatment, in which a clear outcome target was the primary end point and therapeutic consequences of failing to reach the target were predefined; (2) *targets* -- a target could be formulated by clinical, serological, patient-reported, functional, or radiographic variables; individual measures (eg, joint counts or acute phase reactants), composite scores (eg, disease activity score or simplified disease activity index), or response criteria (eg, those defined by the American College of Rheumatology (ACR) or the European League Against Rheumatism) were considered alike; (3) *outcomes* -- Clinical, functional, serological and/or radiographic changes, as defined in the respective trials, were compared between treatment groups.

Implementation of the systematic literature review {#s4}
--------------------------------------------------

We searched Medline, Embase and Cochrane databases from their inception until December 2008. Additionally, ACR and European League Against Rheumatism (EULAR) abstracts of 2007 and 2008 were screened. The search was limited to humans, adults and the English language. Detailed inclusion and exclusion criteria and the list of search strings are shown in supplementary tables (tables S1 and S2). We did not exclude studies based on quality.

From the identified strategy trials, data were extracted concerning definitions of targets and success rates of applied strategies.

Results {#s5}
=======

We retrieved 5881 citations for further evaluation ([figure 1](#F1){ref-type="fig"}). Title and abstract screening according to our selection criteria (supplementary table S1) left 76 papers for detailed review. Among those, 17 trials published in full and 2 abstracts addressed direct assessment of treating to target. By hand search of references, we identified three additional papers; further, one full paper and one abstract were included based on expert opinion. This gave a total of 24 publications for this review ([figure 1](#F1){ref-type="fig"}), of which only 7 were strategic trials: 4 trials randomised patients to routine or targeted treatment,[@R26]--[@R29] two compared different randomised targets[@R30] [@R31] and one compared targeted treatment to historical control.[@R32]

![Flow chart of the systematic literature search. Illustrated are the results of the initial search and the selection process of abstract screening, full text review and hand search. AB, abstract; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; RA, rheumatoid arthritis.](ard-69-4-0638-fig1){#F1}

Randomised strategic trials comparing targeted versus routine care {#s6}
------------------------------------------------------------------

Only four trials had randomised patients to a targeted treatment algorithm versus routine care. In Tight Control of Rheumatoid Arthritis (TICORA),[@R26] treatment of early RA aimed at low disease activity (LDA) by Disease Activity Score (DAS), comparing DAS-driven treatment adaptations upon monthly assessments with 3-monthly routine care. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA)[@R27] aimed at remission of early RA, comparing monthly treatment adaptation by computerised decision if \>20% (50%) reduction of several variables was not attained with 3-monthly routine care. A cluster randomised trial by Fransen *et al* [@R28] compared the proportion of patients reaching LDA at the end of follow-up and the number of disease-modifying antirheumatic drug (DMARD) changes during 24 weeks (co-primary end points) in outpatient centres using systematic, DAS28-steered treatment protocols with centres providing routine care. The treatment decision in the DAS28-driven group depended on a threshold of 3.2, indicating LDA. Finally, Symmons *et al*[@R29] tested the effect of aggressive versus symptomatic therapy on physical outcome (*Health Assessment Questionnaire* (HAQ)) in established RA. Decisions for treatment adaption were driven by joint count- and C reactive protein (CRP) thresholds. Designs of these trials are depicted in [figure 2](#F2){ref-type="fig"}; baseline characteristics are tabulated in supplementary table S3.

![Design of the seven core clinical trials. (A) TICORA study (Grigor *et al* 2004)[@R26]; (B) CAMERA study (Verstappen *et al* 2007)[@R27]; (C) Fransen *et al* 2005[@R28]; (D) Symmons *et al* 2005[@R29]; (E) Edmonds *et al* 2007 (abstract)[@R31]; (F) van Tuyl *et al* 2008[@R30]; and (G) Stenger *et al* 1998.[@R32] Intensive and routine treatment arms are displayed, red arrows mark the scheduled intervals for target assessment. [Table 1](#T1){ref-type="table"} specifies the targets of trials A--G. AZA, Azathioprine; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; CRP, C reactive protein; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; *IFX*, ifosfamide; LDA, low disease activity; LEF, leflunomide; MTX, methotrexate; NSAID, *non-steroidal anti-inflammatory drug;* sc, subcutaneous; SJC, swollen joint count; sod., sodium; SPZ, sulfinpyrazone; TICORA, tight control of rheumatoid arthritis.](ard-69-4-0638-fig2){#F2}

###### 

Targets and visit intervals (left columns) and clinical, functional and structural outcomes (right columns) of core trials

  Group                                    Treatment-decision driving target                                                                                                                                                       Interval of controls                                           N     Outcomes/final treatment target p Values indicate differences of outcomes between the targeted (T) and the routine group (R)
  ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- ----- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(A\) TICORA[@R26]                                                                                                                                                                                                                                                                                    
  Targeted group (T)                       DAS\<2.4 LDA                                                                                                                                                                            1 Month                                                        55    Clinicaloutcome at 18 months EULAR good response (primary outcome): OR[\*](#T1FN1){ref-type="table-fn"} 5.8 (2.4 to 13.9); 82% targeted (T) versus 44% routine (R); p\<0.0001EULAR remission: OR[\*](#T1FN1){ref-type="table-fn"} 9.7 (3.9 to 23.9), 64% T versus 16% R; p\<0.0001ACR70: OR[\*](#T1FN1){ref-type="table-fn"} 11 (4.5 to 27), 71% T versus 18% R; p\<0.0001 Functional outcome at 18 monthsHAQ change: −0.97±0.8 T versus −0.47±0.9 R; p=0.0025 Radiographic outcome at 18 months; median (IQR)Progression of erosion score: 0.5 (0--3.357) T versus 3 (0.5--8.5) R; p=0.002Change in TSS: 4.5 (1--9.875) T versus 8.5 (2.0--15.5) R; p=0.02Change in JSN: 3.25 (1.125--7.5) T versus 4.5 (1.5--9.0) R; p=0.331
  Routine control group (R)                Opinion of treating rheumatologist                                                                                                                                                      1 Month                                                        55    
  \(B\) CAMERA[@R27]                                                                                                                                                                                                                                                                                    
  Targeted group (T)                       Improvement of number of swollen joints: \>20% compared to previous visit/50% compared to baseline Improvement in 2 out of 3 criteria: ESR, TJC, PGA \>20% compared to previous visit   1 Month                                                        151   Clinicaloutcome at 1 year[†](#T1FN2){ref-type="table-fn"} and at 2 years[‡](#T1FN3){ref-type="table-fn"} Number of patients in remission for 3 months (primary outcome): 35% T versus 14% R; p\<0.001[†](#T1FN2){ref-type="table-fn"} 50% T versus 37% R; p\<0.029[‡](#T1FN3){ref-type="table-fn"}Mean (95% CI) time until remission (months): 10.4 (9.1 to 11.7) T versus 14.3 (12.6 to 16.1) R; p\<0.001Duration (months) of all periods of remission: 11.6 (10.1--13.1) T versus 9.1 (7.6--10.6) R; p=0.025ACR50: 58% T versus 43% R; p\<0.01[†](#T1FN2){ref-type="table-fn"} 46% T versus 45% R; p=NS[‡](#T1FN3){ref-type="table-fn"} Functional outcome at 1 year[†](#T1FN2){ref-type="table-fn"} and at 2 years[‡](#T1FN3){ref-type="table-fn"}HAQ mean±SD-change: −0.44±0.59 T versus −0.39±0.66 R; p=NS[†](#T1FN2){ref-type="table-fn"}; −0.41±0.64 T versus −0.42±0.76 R; p=NS[‡](#T1FN3){ref-type="table-fn"} Radiographic outcome at 2 yearsAnnual radiographic progression: median (IQR) change (units/year): 0 (0--2.0) T versus 0 (0--2.5) R; p=0.9
  Routine control group (R)                Decrease of SJC, if number of SJ unchanged, assessors\' judgement, looking at TJC, ESR, PGA                                                                                             3 Months                                                       148   
  \(C\) Fransen *et al*[@R28]                                                                                                                                                                                                                                                                           
  Targeted group (T)                       DAS28\<3.2 LDA                                                                                                                                                                          1 Month starting, then 2 months, then 3 months (both groups)   205   Clinicaloutcome at 24 weeks Patients in DAS28/LDA: 31% T versus 16% R; p=0.028Mean±SD changes in DAS28: −0.4±1.0 T versus −0.14±1.2 R; p=0.36DMARD changes: 20% T versus 9% R; p=0.013 Functional data: NR (NS) Radiographic: NR
  Routine control group (R)                Opinion of treating rheumatologist                                                                                                                                                      179                                                                  
  \(D\) Symmons *et al*[@R29]                                                                                                                                                                                                                                                                           
  Targeted group (T)                       CRP\<twice the upper limit of normal range TJC=0 and SJC=0 Symptom control                                                                                                              At least every 4 months (both groups)                          233   Clinicaloutcome at 3 years: (adjusted mean difference (95% CI)) EGA: 3.76 (0.03--7.52); p=0.045OSRA: 0.41 (0.01--0.71); p=0.010SJC, TJC, ESR and PGA: p=NS Functional outcome at 3 years:HAQ (primary outcome): sign deterioration in both arms; mean difference between T and R: p=0.82 Radiographic outcome at 3 years:Total Larsen score: deterioration in both arms of (significant in routine group (p=0.035) but not in the targeted group (p=0.093); difference T versus R: p=NSEroded joint count: increased slightly in both treatment arms, difference T versus R: p=NS
  Routine control group (R)                Symptom control                                                                                                                                                                         233                                                                  
  \(E\) Edmonds *et al*[@R31] (abstract)                                                                                                                                                                                                                                                                
  Targeted group I                         CRP normal range                                                                                                                                                                        1 Month (both groups)                                          82    Clinicaloutcome at 2 years: Target 'SJC\<3' was met in 29%, target 'normal CRP' in 41% of visits (p: NA) Functional outcomes: NR Radiographic outcomes at 2 yearsRadiographic progression scores NS between study arms but: erosion progression 0.2±1.0 versus 1.0±2.5 (p\<0.03), JSN 0.3±1.3 versus 1.2±2.6 (p\<0.03), total score 0.5±1.6 versus 2.2±4.2 (p\<0.005) if AUC-CRP target achieved, as compared to not achieved (not the case for SJC-target) (p NA).
  Targeted group II                        SJC \<3                                                                                                                                                                                 85                                                                   
  Routine control group                    --                                                                                                                                                                                      82                                                                   
  \(F\) van Tuyl *et al*[@R30]                                                                                                                                                                                                                                                                          
  Targeted group I                         DAS28\<3.2 LDA                                                                                                                                                                          8 Weeks, then 13 weeks (both groups)                           11    Clinicaloutcomes at 40 weeks Remission rates: in both targeted arms: 90% (after 8 and 21 weeks: 57% and 76%)ACR20/50/70/90: 100%/95%/71%/43% Functional outcomes: NR Radiographic outcomes: NR
  Targeted group II                        Cartilage degradation: CTX-II excretion ≤150 nmol/mmol creatinine                                                                                                                       10                                                                   
  \(G\) Stenger *et al*[@R32]                                                                                                                                                                                                                                                                           
  Targeted group (T)                       CRP decrease \>50%                                                                                                                                                                      8 Weeks (both groups)                                          139   Clinicaloutcomes at 1 year[†](#T1FN2){ref-type="table-fn"} and at 2 years[‡](#T1FN3){ref-type="table-fn"} AUC-CRP (mg (week/l; median (range)): 1136 (144--3563) T versus 1836 (26--8051) R; p=0.02[†](#T1FN2){ref-type="table-fn"}; 1963 (212--8515) T versus 3025 (46--15632) R; p=0.002[‡](#T1FN3){ref-type="table-fn"} Functional outcomes: NR Radiographic outcomes at 1 year[†](#T1FN2){ref-type="table-fn"} and at 2 years[‡](#T1FN3){ref-type="table-fn"}Median (range) progression rate: 17.0 (0--74) T versus 17.5 (0--130) R; p=0.22[†](#T1FN2){ref-type="table-fn"} 26.0 (0--100) T versus 35 (1--188) R; p=0.03[‡](#T1FN3){ref-type="table-fn"}
  Routine control group (R)                Opinion of treating rheumatologist                                                                                                                                                      89                                                                   

OR (95% CI);

outcome at 1 year;

outcome at 2 years.

AUC, area under the curve; ACR, American College of Rheumatology; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; CRP, C reactive protein; CTX-II, C-terminal cross-linking of type II collagen; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drugs; EGA, evaluator global assessment; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JSN, joint space narrowing; LDA, low disease activity; NR, not reported; OSRA, overall status in rheumatoid arthritis; PGA, physician\'s global assessment; SJC, swollen joint count; TICORA, tight control of rheumatoid arthritis; TJC, total joint count; TSS, total Sharp score.

Characteristics of the core trials, including treatment targets and visit intervals, as well as clinical, functional and radiographic outcomes are summarised in [table 1](#T1){ref-type="table"} and will be detailed below.

Significantly greater DAS reduction and higher likeliness to achieve remission following intensive disease management was evident in all four trials. In TICORA,[@R26] the primary end point, EULAR good response, as well as DAS remission were significantly more frequent upon intensive than routine care. CAMERA[@R27] showed significant benefits of targeted treatment regarding its primary end point, remission for 3 months. Fransen *et al*[@R28] showed that both the proportion of patients reaching LDA and frequency of DMARD changes during follow-up favoured a DAS28-driven DMARD strategy. Symmons *et al*[@R29] found significant differences in clinical outcomes in the evaluator global assessment, while other measures, including joint counts, *erythrocyte sedimentation rate* and patient global visual analogue scale, were not significantly different.

*Physical function* was the primary outcome in the trial by Symmons *et al*[@R29]; the intensive group failed to show significant differences compared to routine care regarding HAQ changes. Also CAMERA[@R27] did not show significant differences in functional outcomes.

Grigor *et al*[@R26] reported significantly less progression of radiographic changes[@R26] in the intensive treatment group. In contrast, no significant differences in annual radiographic progression were described in the CAMERA study.[@R27] Two of the studies did not report radiographic data[@R28] [@R29] ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}).

Randomised strategic trials comparing two targeted strategies {#s7}
-------------------------------------------------------------

van Tuyl *et al*[@R30] presented a study protocol randomising early RA patients to different targeted and tight monitoring schedules: one group aiming at DAS28 remission, the other at suppressing cartilage degradation as assessed by measuring urinary C-terminal cross-linking of type II collagen. Results did not differ significantly between the two groups with similar overall remission rates in both arms ([figure 2](#F2){ref-type="fig"}, [table 1](#T1){ref-type="table"}). However, as the authors concede, this was a very small pilot study. Similarly, Edmonds *et al*[@R31] reported in abstract form on steering at normal CRP levels versus a joint count targeted approach. Their results suggested that targeting CRP provides better interference with radiographic damage ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}).

Non-randomised cohort studies comparing two targeted strategies {#s8}
---------------------------------------------------------------

Stenger *et al*[@R32] compared an aggressive treatment protocol that stipulated change of DMARD therapy if after 8 weeks CRP decrease was less than 50% in patients with a high risk of developing aggressive disease; the comparator arm on regular therapy was a retrospectively assessed group of high risk patients. After 2 years, the area under the curve for CRP was significantly lower in the intensive treatment group than in the historic control. While no functional data were provided, the reported radiographic progression favoured the intensive treatment ([table 1](#T1){ref-type="table"}).

Additional studies {#s9}
------------------

A number of studies used the treat to target concept, but, in contrast to the mentioned papers, did not have a non-targeted control arm, since all arms pursued the same target with different treatment sequences (supplementary table S4). Likewise, several trials compared step-up with combination regimes, dose titration of agents or different therapies to reach a defined target without directly addressing the efficacy of treating to target. A description of these studies can be found in the supplementary material accompanying this manuscript.

Discussion {#s10}
==========

Our review revealed that only few controlled studies investigated the value of strategic treatment schedules. Importantly, study designs and evaluated targets were very heterogeneous; for example, the Edmonds and van Tuyl studies are inherently different in design as compared to the others in that their approach compares two T2T approaches while the others compare a T2T approach with the routine approach. Nevertheless, all studies investigating early disease showed significantly better clinical outcomes of the targeted approach. Functional outcomes, reported in two trials, failed to show significant gains.[@R27] [@R29] Four studies compared radiographic outcomes,[@R26] [@R27] [@R29] [@R32] of which two showed a significant benefit of the targeted therapy.[@R26]

Five[@R26]--[@R28] [@R30] [@R32] studies investigated early disease (using different definitions of 'early' -- see supplementary table S3). Only one trial[@R29] focused explicitly on late disease (duration: \>5 years) and found no advantage of tight control on functional outcomes. Thus, patients with established RA seem to be underinvestigated regarding the value of treating to a target. Since longer disease duration impairs treatment outcomes,[@R33] extending results from early RA to the general patient population could be misleading. Furthermore, just focusing on HAQ might also be misguiding, since with increasing disease duration responsiveness of physical function to therapeutic interventions decreases (even to placebo levels).[@R34]

Utilised targets showed considerable heterogeneity ([table 1](#T1){ref-type="table"}, [figure 2](#F2){ref-type="fig"}). Among the randomised trials comparing targeted versus routine approaches, three out of four employed state targets,[@R26] [@R28] [@R29] an approach that has been favoured as being more appropriate than assessing changes from baseline.[@R35] Only in CAMERA,[@R27] the target was formulated as reaching defined improvement criteria. Also, visit intervals were noticeably heterogenous: clinical assessments were performed from monthly[@R26]--[@R28] [@R31] to every 4[@R29] [@R36] months. Two trials randomised patients to different visit intervals.[@R26] [@R37] In both, patients assigned to intensive strategy were seen monthly, those in routine care every 3 months.

In conclusion, only few studies have used a randomised approach to test the value of treatment to a specific target. However, all of them provided compelling evidence of clinical benefits of such an approach. However, more data are needed concerning radiographic and functional outcomes and patients with longstanding RA have not been sufficiently investigated.
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